Kenneth Marek News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The absence of any biomarker capable of detecting Parkinson's in the earliest stages has hindered finding new treatments. This may be about to change.

The Michael J. Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise. The new test, known as the alpha-synuclein seed amplification assay (?Syn-SAA), heralds the revolutionary ability for research to define Parkinson's disease biologically, offering a critical tool for clinical trial design and assessmen...

A study sponsored by The Michael J. Fox Foundation finds a test of spinal fluid may be able to predict who is likely to develop Parkinson’s disease.

New paper in The Lancet Neurology confirms that a key Parkinson's pathology can now be identified by examining spinal fluid from living patients Test validated...

New paper in The Lancet Neurology confirms that a key Parkinson's pathology can now be identified by examining spinal fluid from living patientsTest validated in the gold-standard Parkinson's